NOVN - ノバン (Novan Inc.)

NOVNのニュース

   Novartis : Alcon Pay $347 Million to Settle Bribery Probes -- Update | MarketScreener  2020/06/25 21:54:00 MarketScreener
By Dylan Tokar and Micah Maidenberg Novartis AG and a former subsidiary of the Swiss drugmaker agreed to pay a combined $347 million to resolve allegations that the companies ran schemes to… | June 25, 2020
   Swiss Pharma Giant Novartis to Pay $112Mln to Settle Bribery Charges - US Regulator  2020/06/25 18:40:09 UrduPoint
   Novartis to pay $336 mn in US settlements on bribes  2020/06/25 18:36:14 RTL Today
   Novartis Units to Pay $347 Million to Resolve U.S. Bribery Probe - BNN Bloomberg  2020/06/25 17:26:50 BNN Bloomberg
Novartis AG and two of its subsidiaries admitted to overseas bribery schemes and agreed to pay about $347 million to settle U.S. criminal and regulatory investigations.
   Novartis, former unit to pay $346 million to resolve US bribery charges | Kathimerini  2020/06/25 17:20:13 ekathimerini.com
Novartis AG and a former unit will pay more than $346 million to resolve US criminal and civil charges they bribed doctors, hospitals and clinics to prescribe their drugs and use their surgical products, US authorities announced on Thursday.
   Novartis Gets EC Approval for Gene Therapy Zolgensma in SMA  2020/05/19 14:52:00 Zacks Investment Research
Novartis' (NVS) gene therapy, Zolgensma, obtains EC approval for spinal muscular atrophy.
   Novartis : Zolgensma Gets Conditional EU Approval | MarketScreener  2020/05/19 06:05:03 MarketScreener
By Olivia Bugault Novartis AG said Tuesday that its Zolgensma gene therapy for patients with spinal muscular atrophy has been conditionally approved in Europe. The European Commission… | May 19, 2020
   Regenerative Medicine Industry Outlook to 2025 Featuring Novartis, Vericel, Integra Lifesciences, Mimedx Group, Stryker, Wright Medical, Roche and More  2020/05/14 13:00:00 PR Newswire
DUBLIN, May 14, 2020 /PRNewswire/ -- The "Global Regenerative Medicine Market By Therapy (Cell-Based Immunotherapy & Cell Therapy, Gene Therapy, Others), By Application, By Material, By Cell, By Product, By Technique, By Distribution Channel, By Region, Forecast & Opportunities, 2025"…
   Dyno Therapeutics Announces Ocular Collaboration with Novartis to Develop Improved Gene Therapies with AAV Vectors based on AI Technology  2020/05/11 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyno Therapeutics Announces Ocular Collaboration with Novartis to Develop Improved Gene Therapies with AAV Vectors based on AI Technology
   The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight  2020/05/10 19:40:37 Benzinga
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) gained about 6% for the week. Large-cap pharma names AstraZeneca plc (NYSE: AZN ) and Novartis AG (NYSE: NVS ) received FDA nods for their heart failure and lung cancer therapies, respectively. After receiving emergency use authorization from the FDA in the U.S., Gilead Sciences, Inc.'s (NASDAQ: GILD ) remdesivir obtained full regulatory approval in Japan. Moderna Inc (NASDAQ: MRNA ) received the OK to proceed with the Phase 2 trial of its mRNA coronavirus vaccine candidate mRNA-1273. The following are the key events and catalysts that biotech investors need to watch in the coming week. Conferences Bank of America Securities 2020 HealthCare Virtual Conference: May 12-14 American Society of Gene and Cell Therapy, or ASGCT, 23rd Virtual Annual Meeting: May 12-15 2020 Society for Investigative Dermatology, or SID, Annual Meeting Virtual Conference: May 13-16 Society for Cardiovascular Angiography and Interventions, or SCAI, 2020 Virtual Conference, Scientific Sessions: May 14-16 PDUFA Dates Clovis Oncology Inc (NASDAQ: CLVS ) awaits the FDA nod for an expanded indication for its cancer therapy Rubraca .
   FDA OKs Novartis' osilodrostat for adrenal gland disorder  2020/03/07 15:40:04 Seeking Alpha
The FDA approves Novartis' (NYSE:NVS) Isturisa (osilodrostat) oral tablets for the treatment of adults with Cushing's disease who either cannot undergo pit
   Orionis Biosciences Debuts with Major Pharmaceutical Collaboration to Tackle Industry’s Most Challenging Protein Targets  2020/03/05 13:00:00 Business Wire
BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences is today debuting with the announcement of a major drug discovery collaboration with Novartis.
   We need short-term launches to keep driving growth: Novartis CEO  2020/03/04 08:13:00 Business Today
One of Novartis' success stories in India has been our emerging market brands approach, which enables us to use a distinctive brand and distinct product presentation to (differentially) price (innovative medicines) for the Indian market
   Sanofi just got its first cancer drug approved in a decade. Here's the pharma giant's plan to rejoin the fight against cancer under new CEO Paul Hudson.  2020/03/03 17:51:00 Business Insider
The French drugmaker Sanofi has officially re-entered oncology, as the Food and Drug Administration approved the multiple myeloma treatment Sarclisa on Monday. Sanofi's last new cancer drug was a chemotherapy approved a decade ago. Under new leadership, the company plans to advance several more cancer therapies, a top Sanofi executive told Business Insider. "Sarclisa is our re-entry into oncology," Sanofi's development leader Dietmar Berger said in an interview. "You see a very meaningful pipeline behind that." In his first few months as CEO, Paul Hudson has begun shaking up the $120 billion pharma giant. In December, he announced Sanofi will stop diabetes and cardiovascular research , while inking a $2.5 billion deal to acquire Synthorx and expand its immuno-oncology pipeline. Click here for more BI Prime stories . Sanofi is back in the fight against cancer. On Monday, the French pharmaceutical giant won US approval for Sarclisa, a therapy for a type of blood cancer called multiple myeloma.
   Sandoz to pay $195M in price-fixing case  2020/03/03 12:45:58 Seeking Alpha
Novartis (NYSE:NVS) unit Sandoz has agreed to pay a criminal penalty of $195M to settle a federal generic drug price-fixing case. The U.S. Department of Ju

calendar